Literature DB >> 15765775

The effect of antiplatelet autoantibodies on megakaryocytopoiesis.

Robert McMillan1, Diane Nugent.   

Abstract

Immune thrombocytopenic purpura (ITP) is a disorder manifested by isolated thrombocytopenia. In vivo infusion studies in the 1950s and 1960s provided evidence that the thrombocytopenia was due to autoantibody-induced platelet destruction. However, there is mounting evidence that platelet production in this disorder may also be suppressed by antibodies. Early morphologic studies showed megakaryocytic damage in ITP, and these results have been confirmed by ultrastructural studies. Autologous platelet turnover studies in the 1980s showed that most ITP patients have either normal or reduced platelet turnover rather than increased turnover, as would be expected if platelet destruction were the only pathogenetic mechanism. More recently, in vitro culture studies of both adult and pediatric ITP have shown that some ITP plasmas suppress both megakaryocytopoiesis and thrombopoiesis. In view of these findings, both platelet destruction and suppression of platelet production seem likely to be involved in the pathogenesis of ITP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765775     DOI: 10.1532/ijh97.04168

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  30 in total

1.  Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Authors:  Robert McMillan; Lei Wang; Aaron Tomer; Janet Nichol; Jeanne Pistillo
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

2.  Splenic macrophages in thrombocytopenia.

Authors:  B G Firkin; R Wright; S Miller; E Stokes
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

3.  Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies.

Authors:  N R Shulman; V J Marder; R S Weinrach
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

4.  Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ.

Authors:  A du P Heyns; P N Badenhorst; M G Lötter; H Pieters; P Wessels; H F Kotzé
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

5.  Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies.

Authors:  R Hoffman; E Mazur; E Bruno; V Floyd
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

6.  In vitro platelet phagocytosis in idiopathic thrombocytopenic purpura.

Authors:  T Tsubakio; Y Kurata; Y Kanayama; T Yonezawa; S Tarui; T Kitani
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

7.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

8.  Incomplete antigenic cross-reactivity between platelets and megakaryocytes: relevance to ITP.

Authors:  C P Stahl; D Zucker-Franklin; T P McDonald
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

9.  Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients.

Authors:  W Vainchenker; J F Deschamps; J M Bastin; J Guichard; M Titeux; J Breton-Gorius; A J McMichael
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

10.  Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia.

Authors:  G Zauli; L Catani; D Gibellini; M C Re; N Vianelli; V Colangeli; C Celeghini; S Capitani; M La Placa
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more
  11 in total

1.  A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.

Authors:  Naruko Suzuki; Junji Hiraga; Yumi Hariyama; Yusuke Takagi; Haruhiko Ohashi; Yasuyuki Kishigami; Hidenori Oguchi; Yoshitoyo Kagami
Journal:  Int J Hematol       Date:  2017-11-29       Impact factor: 2.490

Review 2.  [Adult autoimmune thrombocytopenia: diagnosis and treatment].

Authors:  Klaus Lechner; Ansgar Weltermann; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.

Authors:  V Noronha; S D Philip; A Joshi; K Prabhash
Journal:  Int J Hematol       Date:  2012-08-01       Impact factor: 2.490

4.  Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database.

Authors:  Ameet Sarpatwari; Dimitri Bennett; John W Logie; Amit Shukla; Kathleen J Beach; Adrian C Newland; Simon Sanderson; Drew Provan
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 5.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

6.  Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.

Authors:  Emma C Josefsson; Chloé James; Katya J Henley; Marlyse A Debrincat; Kelly L Rogers; Mark R Dowling; Michael J White; Elizabeth A Kruse; Rachael M Lane; Sarah Ellis; Paquita Nurden; Kylie D Mason; Lorraine A O'Reilly; Andrew W Roberts; Donald Metcalf; David C S Huang; Benjamin T Kile
Journal:  J Exp Med       Date:  2011-09-12       Impact factor: 14.307

7.  Patient-reported treatment burden of chronic immune thrombocytopenia therapies.

Authors:  T Michelle Brown; Ruslan V Horblyuk; Kelly M Grotzinger; Axel C Matzdorff; Chris L Pashos
Journal:  BMC Blood Disord       Date:  2012-03-22

8.  A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation.

Authors:  Susan D Mathias; James B Bussel; James N George; Robert McMillan; Gary J Okano; Janet L Nichol
Journal:  Health Qual Life Outcomes       Date:  2007-02-22       Impact factor: 3.186

9.  Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia.

Authors:  Yanan Wang; Fengqi Liu; Gaochao Zhang; Yan Su; Xueyan Sun; Qi Chen; Chencong Wang; Haixia Fu; Yun He; Xiaolu Zhu; Xiao Liu; Meng Lv; Xiangyu Zhao; Xiaosu Zhao; Yueying Li; Qianfei Wang; Xiaojun Huang; Xiaohui Zhang
Journal:  Sci China Life Sci       Date:  2020-08-25       Impact factor: 6.038

Review 10.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.

Authors:  Sylvain Audia; Matthieu Mahévas; Martin Nivet; Sethi Ouandji; Marion Ciudad; Bernard Bonnotte
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.